Bimatoprost Versus Travoprost at Cairo University
|ClinicalTrials.gov Identifier: NCT01092273|
Recruitment Status : Completed
First Posted : March 24, 2010
Last Update Posted : March 24, 2010
Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.
These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).
|Condition or disease|
|Glaucoma Ocular Hypertension|
|Study Type :||Observational|
|Official Title:||Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective Randomized Study.|
|Bimatoprost versus Travoprost|
- Percentage of intraocular pressure lowering of bimatoprost versus travoprost.
- Rate of development of complications.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092273
|Cairo, Egypt, 11431|